With recent product approvals and the development of new chemistries and delivery technologies, the RNA-based drugs sector is undergoing rapid change, and UK-based Silence Therapeutics is aiming to be part of that evolution.
The RNA-based drugs sector is believed to be approaching a tipping point, with new chemistries and better delivery technologies being developed, and that’s one of the reasons the UK RNA-based therapeutics biotech, Silence Therapeutics PLC, is keen on new technologies being developed by US firm Arrowhead Pharmaceuticals Inc.
Silence has bought an 8.4% stake in Arrowhead for £7.8m ($9.6m), thereby signaling its interest in Arrowhead. Acquisition of the...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
